PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18277626-0	2007	[Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].	fludarabine	200-211	fibroblast growth factor 2	Homo sapiens	1-31	
18277626-8	2007	In twelve patients who achieved at least partial response after intensive fludarabine-based treatment, levels of bFGF as well as VEGF decreased significantly (bFGF, p = 0.0005; VEGF, p = 0.0068); in addition, they were no more significantly different from controls (bFGF, p = 0.524; VEGF, p = 0.728).	fludarabine	74-85	fibroblast growth factor 2	Homo sapiens	113-117	
18277626-8	2007	In twelve patients who achieved at least partial response after intensive fludarabine-based treatment, levels of bFGF as well as VEGF decreased significantly (bFGF, p = 0.0005; VEGF, p = 0.0068); in addition, they were no more significantly different from controls (bFGF, p = 0.524; VEGF, p = 0.728).	fludarabine	74-85	fibroblast growth factor 2	Homo sapiens	159-163	
18277626-8	2007	In twelve patients who achieved at least partial response after intensive fludarabine-based treatment, levels of bFGF as well as VEGF decreased significantly (bFGF, p = 0.0005; VEGF, p = 0.0068); in addition, they were no more significantly different from controls (bFGF, p = 0.524; VEGF, p = 0.728).	fludarabine	74-85	fibroblast growth factor 2	Homo sapiens	159-163	
18277626-0	2007	[Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].	fludarabine	200-211	fibroblast growth factor 2	Homo sapiens	33-37	
18277626-4	2007	The objective of the present study was to quantify plasma levels of key angiogenic activators vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with CLL and determine their potential change after intensive fludarabine-based treatment.	fludarabine	252-263	fibroblast growth factor 2	Homo sapiens	140-170	
9009090-1	1997	Basic fibroblast growth factor (bFGF) is a pleiotropic cytokine which has recently been shown to delay fludarabine-induced apoptosis in B cell chronic lymphocytic leukemia (B-CLL) cells.	fludarabine	103-114	fibroblast growth factor 2	Homo sapiens	0-30	
9009090-1	1997	Basic fibroblast growth factor (bFGF) is a pleiotropic cytokine which has recently been shown to delay fludarabine-induced apoptosis in B cell chronic lymphocytic leukemia (B-CLL) cells.	fludarabine	103-114	fibroblast growth factor 2	Homo sapiens	32-36	
9009090-3	1997	Viability data of cells treated with fludarabine alone or in combination with bFGF demonstrated that the addition of bFGF to the cells resulted in prolonged survival.	fludarabine	37-48	fibroblast growth factor 2	Homo sapiens	117-121	
9009090-4	1997	Quantitative assessment of apoptosis-associated DNA strand breaks by in situ TdT labeling showed a protective effect of bFGF on fludarabine-treated cells.	fludarabine	128-139	fibroblast growth factor 2	Homo sapiens	120-124	
9009090-9	1997	In addition, exposure of cells from three patients with B-CLL to bFGF showed an upregulation of bcl-2 protein after 4-8 h. Our data demonstrate that bFGF upregulates the expression of bcl-2 in these cells, suggesting that this increase in bcl-2 expression may play a role in the delay of fludarabine-induced apoptosis.	fludarabine	288-299	fibroblast growth factor 2	Homo sapiens	65-69	
9009090-9	1997	In addition, exposure of cells from three patients with B-CLL to bFGF showed an upregulation of bcl-2 protein after 4-8 h. Our data demonstrate that bFGF upregulates the expression of bcl-2 in these cells, suggesting that this increase in bcl-2 expression may play a role in the delay of fludarabine-induced apoptosis.	fludarabine	288-299	fibroblast growth factor 2	Homo sapiens	149-153	
8562930-0	1996	Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine.	fludarabine	154-165	fibroblast growth factor 2	Homo sapiens	32-62	
8562930-10	1996	CLL cells with high intracellular levels of bFGF appeared to be more resistant to fludarabine treatment.	fludarabine	82-93	fibroblast growth factor 2	Homo sapiens	44-48	
8562930-11	1996	The addition of bFGF to fludarabine-treated CLL cells resulted in a delay of apoptosis and prolonged survival.	fludarabine	24-35	fibroblast growth factor 2	Homo sapiens	16-20